<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-2077</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АРТЕРИАЛЬНАЯ ГИПЕРТОНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTERIAL HYPERTENSION</subject></subj-group></article-categories><title-group><article-title>Комбинации аллелей генов NOS3 и CYBA и риск развития эссенциальной артериальной гипертонии у мужчин</article-title><trans-title-group xml:lang="en"><trans-title>Combinations of NOS3 and CYBA alleles and essential hypertension risk in men</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Макаревич</surname><given-names>П. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Makarevich</surname><given-names>P. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант факультета фундаментальной медицины</p></bio><email xlink:type="simple">pavel.makarevich@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреенко</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreenko</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант факультета фундаментальной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балацкий</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Balatsky</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор Российского кардиологического научно-производственного комплекса</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Колотвин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kolotvin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант факультета прикладной биотехнологии</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Попова</surname><given-names>Н. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Popova</surname><given-names>N. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>студент факультета фундаментальной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яровая</surname><given-names>Е. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Yarovaya</surname><given-names>E. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры теории вероятности механико-математического</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Самоходская</surname><given-names>Л. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Samokhodskaya</surname><given-names>L. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доцент кафедры медицинской и биологической химии факультета фундаментальной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ткачук</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tkachuk</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>декан факультета фундаментальной медицины</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Московский государственный университет имени М. В. Ломоносова. Москва</institution></aff><aff xml:lang="en"><institution>M.V. Lomonosov Moscow State University. Moscow</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2010</year></pub-date><pub-date pub-type="epub"><day>20</day><month>06</month><year>2010</year></pub-date><volume>9</volume><issue>3</issue><fpage>4</fpage><lpage>9</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Макаревич П.И., Андреенко Е.Ю., Балацкий А.В., Колотвин А.В., Попова Н.О., Яровая Е.Б., Самоходская Л.М., Ткачук В.А., 2010</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="ru">Макаревич П.И., Андреенко Е.Ю., Балацкий А.В., Колотвин А.В., Попова Н.О., Яровая Е.Б., Самоходская Л.М., Ткачук В.А.</copyright-holder><copyright-holder xml:lang="en">Makarevich P.I., Andreenko E.Y., Balatsky A.V., Kolotvin A.V., Popova N.O., Yarovaya E.B., Samokhodskaya L.M., Tkachuk V.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/2077">https://cardiovascular.elpub.ru/jour/article/view/2077</self-uri><abstract><p>Цель. Оценить роль точечных замен Glu298Asp и C242T и их комбинаций в формировании предрасположенности к развитию эссенциальной артериальной гипертонии (АГ). Материал и методы. Обследованы 511 мужчин в возрасте 19—61 года: 409 больных с подтвержденным диагнозом АГ — основная группа (ОГ) и группа контроля (ГК) — 102 практически здоровых мужчины без заболеваний сердечно-сосудистой системы (средний возраст 36,2±5,5). Для определения аллельных вариантов исследуемых генов использовался метод полимеразной цепной реакции с анализом длины рестрикционных фрагментов. Результаты. Среди больных ОГ частота мутантного аллеля 298Asp составила 22,8 % vs 24,2 % в ГК (р&gt;0,05). Мутантный аллель 242Т встречался в 31,8 % и 37,8 % в ОГ и ГК, соответственно (p&gt;0,05). Анализ сочетаний генотипов показал, что комбинации, в которых количество мутантного аллеля 298Asp выше мутантного аллеля 242Т, могут увеличивать риск развития АГ. С использованием бинарной логистической регрессионной модели были определены отношение шансов (ОШ) и доверительные интервалы (ДИ). Значимость модели (p) оценивали с помощью метода максимального правдоподобия. У лиц с комбинациями генотипов с “преобладанием” мутации гена NOS3 повышен риск развития АГ — ОШ=1,55; 95 %ДИ 1,00—2,40 (p=0,049). В число неблагоприятных генотипов попали 298Het/242Wt; 298Mut/242Het; 298Mut/242Wt и 298Wt/242Het. Заключение. Точечные мутации Glu298Asp и C242T не являются значимыми факторами, повышающими риск АГ у мужчин. Однако выявлены комбинации генотипов, которые могут быть неблагоприятными для формирования АГ.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study the role of Glu298Asp and C242T point substitutions and their combinations in the development of essential arterial hypertension (AH). Material and methods. The study included 511 men aged 19—61 years (mean age 36,2±5,5 years): 409 patients with confirmed AH diagnosis (main group, MG), and 102 healthy men without cardiovascular disease (control group, CG). Alleles of interest were identified using polymerase chain reaction and restriction fragment length analysis. Results. Among AH patients, the prevalence of mutant allele 298Asp was 22,8 %, vs. 24,2 % in the CG (р&gt;0,05). The prevalence of mutant allele 242Т was 31,8 % and 37,8 % in MG and CG, respectively (p&gt;0,05). The combinations where mutant allele 298Asp outnumbered mutant allele 242Т were shown to increase AH risk. In the binary logistic regression model, AH odds ratio and confidence intervals were calculated. The p value of the model was assessed with maximal likelihood test. In people with “prevalent” NOS3 mutation, AH risk was higher (OR 1,55; 95 %CI 1,00—2,40; p=0,049). Adverse genotypes included 298Het/242Wt; 298Mut/242Het; 298Mut/242Wt и 298Wt/242Het. Conclusion. Point mutations of Glu298Asp and C242T did not increase AH risk in men substantially. However, other genotype combinations, associated with increased AH risk, were identified.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертония</kwd><kwd>полиморфизм</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>polymorphism</kwd><kwd>risk factors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Leusen JH, Verhoeven AJ, Roos D. Interactions between the components of the human NADPH oxidase: intrigues in the phox family. J Lab Clin Med 1996; 128(5): 461—76.</mixed-citation><mixed-citation xml:lang="en">Leusen JH, Verhoeven AJ, Roos D. Interactions between the components of the human NADPH oxidase: intrigues in the phox family. J Lab Clin Med 1996; 128(5): 461—76.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10(6): 1115—26.</mixed-citation><mixed-citation xml:lang="en">Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydrobiopterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008; 10(6): 1115—26.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002; 53(4 Pt 1): 515—24.</mixed-citation><mixed-citation xml:lang="en">Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J Physiol Pharmacol 2002; 53(4 Pt 1): 515—24.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Л. Ю. Каминская. А. А. Жлоба, Л. А. Александрова и др. Влияние донатора NO нитрозотиола глутатиона на уровень окислов азота и малонового диальдегида в крови крыс. Артер гиперт 2005; 11(1): 10—7.</mixed-citation><mixed-citation xml:lang="en">Л. Ю. Каминская. А. А. Жлоба, Л. А. Александрова и др. Влияние донатора NO нитрозотиола глутатиона на уровень окислов азота и малонового диальдегида в крови крыс. Артер гиперт 2005; 11(1): 10—7.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ghazali DM, Rehman A, Rahman AR. Candidate gene polymorphisms and their association with hypertension in Malays. Clin Chim Acta 2008; 388(1—2): 46—50.</mixed-citation><mixed-citation xml:lang="en">Ghazali DM, Rehman A, Rahman AR. Candidate gene polymorphisms and their association with hypertension in Malays. Clin Chim Acta 2008; 388(1—2): 46—50.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Srivastava K, Narang R, Sreenivas, et al. Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians. Clin Chim Acta 2008; 387(1—2): 80—3.</mixed-citation><mixed-citation xml:lang="en">Srivastava K, Narang R, Sreenivas, et al. Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians. Clin Chim Acta 2008; 387(1—2): 80—3.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Godfrey V, Chan SL, Cassidy A, et al. The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev 2007; 25(3): 280—8.</mixed-citation><mixed-citation xml:lang="en">Godfrey V, Chan SL, Cassidy A, et al. The functional consequence of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene in young healthy volunteers. Cardiovasc Drug Rev 2007; 25(3): 280—8.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Di Castelnuovo A, Soccio M, Iacoviello L, et al. The C242T polymorphism of the p22phox component of NAD (P) H oxidase and vascular risk. Two case-control studies and a metaanalysis. Thromb Haemost 2008; 99(3): 594—601.</mixed-citation><mixed-citation xml:lang="en">Di Castelnuovo A, Soccio M, Iacoviello L, et al. The C242T polymorphism of the p22phox component of NAD (P) H oxidase and vascular risk. Two case-control studies and a metaanalysis. Thromb Haemost 2008; 99(3): 594—601.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Moreno MU, San José G, Fortuño A, et al. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 2006; 24(7): 1299—306.</mixed-citation><mixed-citation xml:lang="en">Moreno MU, San José G, Fortuño A, et al. The C242T CYBA polymorphism of NADPH oxidase is associated with essential hypertension. J Hypertens 2006; 24(7): 1299—306.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Krex D, Ziegler A, König IR, et al. Polymorphisms of the NADPH oxidase P22PHOX gene in a Caucasian population with intracranial aneurysms. Cerebrovasc Dis 2003; 16(4): 363—8.</mixed-citation><mixed-citation xml:lang="en">Krex D, Ziegler A, König IR, et al. Polymorphisms of the NADPH oxidase P22PHOX gene in a Caucasian population with intracranial aneurysms. Cerebrovasc Dis 2003; 16(4): 363—8.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ito D, Murata M, Watanabe K, et al.C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000; 31(4): 936—9.</mixed-citation><mixed-citation xml:lang="en">Ito D, Murata M, Watanabe K, et al.C242T polymorphism of NADPH oxidase p22 PHOX gene and ischemic cerebrovascular disease in the Japanese population. Stroke 2000; 31(4): 936—9.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wolff B, Grabe HJ, Schlüter C, et al. Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens 2005; 23(7): 1361—6.</mixed-citation><mixed-citation xml:lang="en">Wolff B, Grabe HJ, Schlüter C, et al. Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens 2005; 23(7): 1361—6.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Karvonen J, Kauma H, Kervinen K, et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort. J Intern Med 2002; 251(2): 102—10.</mixed-citation><mixed-citation xml:lang="en">Karvonen J, Kauma H, Kervinen K, et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort. J Intern Med 2002; 251(2): 102—10.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Arca M, Conti B, Montali A, et al. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 2008; 28(4): 752—7.</mixed-citation><mixed-citation xml:lang="en">Arca M, Conti B, Montali A, et al. C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease. Arterioscler Thromb Vasc Biol 2008; 28(4): 752—7.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
